Table 4. Pediatric Tumors Reported to Respond to Oxaliplatin*.
| Tumor | Study Phase (No. evaluable)a | Best Response |
|---|---|---|
| Medulloblastoma | ||
| Phase I (5)22 | 1 SD | |
| Phase II (15)24 | 2 PR | |
| Phase I + etoposide (3)26 | 1 CR | |
| Phase II + gemcitabine (14)28 | 1 CRb, 6 SD | |
| Current Phase I (2) | 1 PR | |
| Neuroblastoma | ||
| Phase I (6)22 | 1 SD | |
| Phase I (18)23 | 1 PRc | |
| Phase I + etoposide (3)26 | 2 SD | |
| Phase I + irinotecan (1)27 | 1 SD | |
| Phase I + doxorubicin (3)29 | 1 CR, 1 PR, 1 SD | |
| Phase II (10)25 | 3 SD | |
| Phase II + gemcitabine (12)28 | 5 SD | |
| Current Phase I (8) | 6 SDd | |
| Rhabdomyosarcoma | ||
| Phase I (1)22 | 0e | |
| Phase I + irinotecan (2)27 | 1 CR | |
| Phase I + doxorubicin (2)29 | 0e | |
| Phase II (10)25 | 0e | |
| Phase II + gemcitabine (12)28 | 1 PR | |
| Current Phase I (3) | 2 SDf | |
| Nasopharyngeal carcinoma | ||
| Phase II (4)25 | 0e | |
| Phase I + doxorubicin (1)29 | 1 CR |
a
Oxaliplatin was given alone unless otherwise indicated.
b
PR after course 4, CR after course 7.
c
Stable disease data unavailable.
d
One had unconfirmed PR after course 4 before elective withdrawal.
e
All had progressive disease.
f
One had PR after course 5 and PD after course 6.
*
Tumors with at least one PR or CR are included in this table
Abbreviations: CR, complete response; PR, partial response; SD, stable disease